Neurocrine Biosciences Inc. (NBIX)
Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript
Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript
Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal
Neurocrine Biosciences (NASDAQ:NBIX) has agreed to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash transaction valued at approximately $2.9 billion, it was announced on Monday. Under the terms of the agreement, Neurocrine will pay $53 per share for Soleno, representing a premium of about 34% over Soleno's closing stock price on April 2, 2026, and roughly 51% above its 30-day average.
Neurocrine to Buy Soleno for $2.9 Billion
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion in a move intended to expand its endocrinology and rare-disease portfolio.
Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday.
Neurocrine wants to develop new obesity drugs. It's reportedly nearing an acquisition to accelerate that move.
Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.
Neurocrine Biosciences, Inc. (NBIX) Presents at Stifel 2026 Virtual CNS Forum Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Stifel 2026 Virtual CNS Forum Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neurocrine Biosciences: Growth Beyond Just Ingrezza
Neurocrine Biosciences has successfully diversified beyond Ingrezza, with Crenessity's rapid adoption validating its multi-franchise commercial strategy. NBIX's late-stage neuropsychiatry pipeline, including muscarinic agonist and glutamate modulator programs, appears significantly underappreciated by the market. Ingrezza's revenue growth is slowing due to pricing pressures, but NBIX's robust cash position and pipeline investments support long-term growth into the 2030s.
Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.88 per share, missing the Zacks Consensus Estimate of $2.25 per share. This compares to earnings of $1 per share a year ago.
